PRELUDE THERAPEUTICS INCORPORATED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.3 USD | +0.47% |
|
+15.28% | +0.70% |
Presenter SpeechTazeen Ahmad (Analysts)Okay, everybody, good afternoon. Thanks for sticking ar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Calendar
10:00pm
- Investor Meeting - SMARCA
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
4.28
USD
Average target price
4.75
USD
Spread / Average Target
+10.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.70% | 235M | |
| +31.91% | 50.85B | |
| +0.87% | 42.82B | |
| +48.83% | 42.03B | |
| -4.22% | 29.55B | |
| +10.85% | 26.11B | |
| -22.09% | 19.13B | |
| +7.87% | 13.05B | |
| +26.28% | 12.16B | |
| +23.33% | 12.08B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Transcript : Prelude Therapeutics Incorporated Presents at BofA Securities 2021 Virtual Health Care Conference, May-12-2021 05